Lee Daeyeol MMS — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,275,090	19
2024	Research	$1,791,710	37
2023	Research	$853,455	30
2022	Research	$1,082,349	24
2021	Research	$795,132	27
2020	Research	$264,464	9
2019	Research	$316,172	11

Breakdown

Who paid Research payments · program years 2019–2025

Celgene Corporation $3,489,808 74 payments
E.R. Squibb & Sons, L.L.C. $2,413,357 76 payments
Mirati Therapeutics, Inc. $475,207 7 payments

Studies the money was for Research payments · program years 2019–2025

Study ofCC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma $780,394 1 payment
A Phase 1, open-label, dose finding study of CC-93269, a BCMA X CD3 T Cell engaging antibody, in subjects with relapsed and refractory Multiple Myeloma. $605,393 1 payment
Ph1 Dose Escal/Expan - A Phase 1, open-label, dose finding study of CC-93269, a BCMA X CD3 T Cell engaging antibody, in subjects with relapsed and refractory Multiple Myeloma. $574,035 1 payment
Phase 1 Dose Escalation and Expansion (CC-93269-MM-001) $503,686 3 payments
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation $322,617 3 payments
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 $289,851 2 payments
A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy (VALOR-HCM) $267,636 4 payments
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) $201,466 1 payment
A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung) $187,013 3 payments
A Phase 1, open-label, dose finding study of CC-93 $146,968 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.